United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma.
Int J Lab Hematol
; 36(1): 20-8, 2014 Feb.
Article
in En
| MEDLINE
| ID: mdl-23615178
ABSTRACT
Bendamustine is a unique bifunctional alkylating agent with promising activity in myeloma. Despite the increasing number of studies demonstrating its efficacy in both the upfront and relapse settings, including patients with renal insufficiency, the optimal use of bendamustine, in terms of dosage, schedule and combination with other agents, has yet to be defined. It is currently licensed for use as frontline treatment with prednisolone for patients with myeloma who are unsuitable for transplantation and who are contraindicated for thalidomide and bortezomib. Studies in relapsed/refractory patients are currently ongoing with other combinations. Given the increasing data to date, the UK Myeloma Forum believes that bendamustine with steroids alone or in combination with a novel agent could be considered for patients with multiply relapsed myeloma. This document provides guidance for the use of bendamustine for patients with myeloma until the results of definitive studies are available.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Antineoplastic Agents, Alkylating
/
Induction Chemotherapy
/
Bendamustine Hydrochloride
/
Multiple Myeloma
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
Int J Lab Hematol
Journal subject:
HEMATOLOGIA
Year:
2014
Document type:
Article
Affiliation country:
United kingdom